BioCentury
ARTICLE | Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

The regimen is optimized to induce strong T cell responses as well as strong antibody responses

January 20, 2021 3:00 AM UTC

NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody responses.

The approach could also serve as a shield against the rise of SARS-CoV-2 variants resistant to the first tranche of vaccines...